This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Ratings

10 Best Healthcare Equipment Stocks for 2015

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 healthcare equipment stocks are rated highest by TheStreet Ratings' value-focused stock rating model.

Equity Top: Healthcare Equipment

Source: TheStreet Ratings

Best Investments for 2015

Healthcare Equipment

The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.
9/3/15 6:01AM
Titan and its partner will resubmit Probuphine for FDA approval later this year.
6/8/15 7:01AM
As the CEO of a struggling stem-cell therapy company, Hedrick needs to don brightly colored pom-poms just to grab investors' attention.
4/8/15 2:51PM
Plans to seek U.S. approval for the Ocular device, known as OTX-DP are now up in the air.
4/6/15 5:22PM
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
3/25/15 10:06AM
Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.
3/10/15 10:17AM
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
3/4/15 1:08PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
1/23/15 6:00AM
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
1/12/15 1:35PM
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
12/19/14 9:02AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
12/5/14 6:00AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/21/14 6:00AM
Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.
11/4/14 1:40PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/17/14 7:05AM
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
8/13/14 12:04PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%
Top Rated Stocks Top Rated Funds Top Rated ETFs